Notably, circDNA-based combination therapy induced broader transcriptional modulation compared to controls, simultaneously suppressing emerging HCC-associated oncogenic markers such as KIF, ABL1, ANXA2, and NCAPG (Figure S7B). The gene discussed is ANXA2; the disease is hepatocellular carcinoma.